Johnson & Johnson (JNJ) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $253.28, -0.25% vs the prior close of $253.91.
- Volume 9.27M shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
JNJ ends flat (-0.2%) to $253.28. Closed at $253.28, -0.25% vs the prior close of $253.91. Day range $252.62–$262.45, opened at $257.11.
JNJ daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — JNJ ends flat (-0.2%) to $253.28
- Closed at $253.28, -0.25% vs the prior close of $253.91. Day range $252.62–$262.45, opened at $257.11.
- Volume was 9.27M shares, 1.4x its 50-day average of 6.76M.
- Price is -4.5% vs its 50-day average ($265.26) and +3.9% vs its 200-day average ($243.87).
- 52-week range $184.66–$281.07; today's close sits at 71% of that range, 9.9% below the 52-week high.
Oct 14, 2026 — JNJ rises 2.1% to $253.91
- Closed at $253.91, +2.13% vs the prior close of $248.61. Day range $248.50–$253.94, opened at $249.10.
- Volume was 9.66M shares, 1.4x its 50-day average of 6.72M.
- Price is -4.3% vs its 50-day average ($265.35) and +4.2% vs its 200-day average ($243.64).
- 52-week range $184.66–$281.07; today's close sits at 72% of that range, 9.7% below the 52-week high.
Oct 13, 2026 — JNJ slides 5.7% to $248.61, a 1-month low on 2.5x normal volume
- Closed at $248.61, -5.73% vs the prior close of $263.73. Day range $245.17–$256.18, opened at $254.56.
- Volume was 16.65M shares, 2.5x its 50-day average of 6.55M — unusually heavy trading.
- Price is -6.3% vs its 50-day average ($265.37) and +2.1% vs its 200-day average ($243.41).
- 52-week range $184.66–$281.07; today's close sits at 66% of that range, 11.5% below the 52-week high.
- SEC filings that day: 8-K.
- This was a results day: the company filed an earnings release (8-K Item 2.02).
Oct 12, 2026 — JNJ rises 0.9% to $263.73
- Closed at $263.73, +0.88% vs the prior close of $261.44. Day range $260.37–$264.39, opened at $261.60.
- Volume was 5.90M shares, 0.9x its 50-day average of 6.56M.
- Price is -0.7% vs its 50-day average ($265.48) and +8.4% vs its 200-day average ($243.21).
- 52-week range $184.66–$281.07; today's close sits at 82% of that range, 6.2% below the 52-week high.
Oct 9, 2026 — JNJ rises 1.9% to $261.44
- Closed at $261.44, +1.93% vs the prior close of $256.48. Day range $254.99–$261.61, opened at $255.09.
- Volume was 5.73M shares, 0.9x its 50-day average of 6.61M.
- Price is -1.5% vs its 50-day average ($265.33) and +7.6% vs its 200-day average ($242.92).
- 52-week range $184.66–$281.07; today's close sits at 80% of that range, 7.0% below the 52-week high.
Oct 8, 2026 — JNJ dips 0.8% to $256.48
- Closed at $256.48, -0.76% vs the prior close of $258.45. Day range $251.95–$257.80, opened at $256.22.
- Volume was 6.17M shares, 0.9x its 50-day average of 6.61M.
- Price is -3.3% vs its 50-day average ($265.22) and +5.7% vs its 200-day average ($242.65).
- 52-week range $184.66–$281.07; today's close sits at 74% of that range, 8.7% below the 52-week high.
Oct 7, 2026 — JNJ rises 1.4% to $258.45
- Closed at $258.45, +1.44% vs the prior close of $254.78. Day range $255.73–$260.68, opened at $256.21.
- Volume was 5.40M shares, 0.8x its 50-day average of 6.71M.
- Price is -2.6% vs its 50-day average ($265.40) and +6.6% vs its 200-day average ($242.40).
- 52-week range $182.94–$281.07; today's close sits at 77% of that range, 8.0% below the 52-week high.
Oct 6, 2026 — JNJ rises 0.7% to $254.78
- Closed at $254.78, +0.73% vs the prior close of $252.93. Day range $251.17–$255.48, opened at $254.15.
- Volume was 5.66M shares, 0.8x its 50-day average of 6.79M.
- Price is -4.1% vs its 50-day average ($265.57) and +5.2% vs its 200-day average ($242.15).
- 52-week range $182.94–$281.07; today's close sits at 73% of that range, 9.4% below the 52-week high.
Oct 5, 2026 — JNJ dips 1.2% to $252.93, a 1-month low, 5 down days in a row
- Closed at $252.93, -1.21% vs the prior close of $256.03. Day range $252.51–$256.24, opened at $256.00.
- Volume was 10.03M shares, 1.5x its 50-day average of 6.72M.
- Price is -4.8% vs its 50-day average ($265.79) and +4.5% vs its 200-day average ($241.93).
- 52-week range $182.94–$281.07; today's close sits at 71% of that range, 10.0% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — JNJ dips 1.0% to $256.03, a 1-month low, 4 down days in a row
- Closed at $256.03, -1.02% vs the prior close of $258.66. Day range $255.12–$259.38, opened at $259.38.
- Volume was 10.94M shares, 1.6x its 50-day average of 6.66M.
- Price is -3.7% vs its 50-day average ($266.00) and +5.9% vs its 200-day average ($241.71).
- 52-week range $182.94–$281.07; today's close sits at 74% of that range, 8.9% below the 52-week high.
- That makes 4 straight losses.
JNJ latest news & SEC filings
Every SEC filing by or about JNJ in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Sep 10, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 4, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schmid Timothy sold 22,527 shares at $274.74 (≈$6.19M) on Sep 2, 2026
- Schmid Timothy sold 11,070 shares at $274.74 (≈$3.04M) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 1, 2026 · 3 — Initial insider ownership statement (Form 3)
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 11, 2026 · N-PX — Annual proxy voting record
Annual proxy voting record
Aug 6, 2026 · 13F-HR — Quarterly holdings report filed by an institutional investment manager
Quarterly holdings report filed by an institutional investment manager
Aug 4, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 29, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 28, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 23, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 28, 2026:
- Revenue: $25.31B (prior year $23.74B) (+6.6% vs Jun 29, 2025)
- Net income: $5.53B (prior year $5.54B) (-0.1% vs Jun 29, 2025)
- Diluted EPS: $2.27 (prior year $2.29) (-0.9% vs Jun 29, 2025)
Jul 15, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 25, 2026 · 11-K — Annual report for an employee stock plan
Annual report for an employee stock plan
Things to know before you trade JNJ
- Last results release: Oct 13, 2026 (8-K Item 2.02). Previous ones: Jul 15, 2026, Apr 14, 2026, Jan 21, 2026. Based on that rhythm, the next report is likely around Jan 12, 2027 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.12% (largest 5.7%).
- Liquidity: about 7.82M shares (≈$1.98B) trade per day on average.
- 52-week position: $253.28 vs a range of $184.66–$281.07 (71% of the range).
- Dividends: last ex-dividend date Aug 25, 2026 ($1.34/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Timothy Schmid sold 22,527 shares on Sep 2, 2026.
- Latest filings: 8-K Oct 13, 2026; 8-K Aug 4, 2026; 8-K Jul 29, 2026.
- Share count: 2.41B shares outstanding (Jul 17, 2026), +0.1% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
JNJ market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 257.11 | 262.45 | 252.62 | 253.28 | 9.27M |
| Oct 14, 2026 | 249.10 | 253.94 | 248.50 | 253.91 | 9.66M |
| Oct 13, 2026 | 254.56 | 256.18 | 245.17 | 248.61 | 16.65M |
| Oct 12, 2026 | 261.60 | 264.39 | 260.37 | 263.73 | 5.90M |
| Oct 9, 2026 | 255.09 | 261.61 | 254.99 | 261.44 | 5.73M |
| Oct 8, 2026 | 256.22 | 257.80 | 251.95 | 256.48 | 6.17M |
| Oct 7, 2026 | 256.21 | 260.68 | 255.73 | 258.45 | 5.40M |
| Oct 6, 2026 | 254.15 | 255.48 | 251.17 | 254.78 | 5.66M |
| Oct 5, 2026 | 256.00 | 256.24 | 252.51 | 252.93 | 10.03M |
| Oct 2, 2026 | 259.38 | 259.38 | 255.12 | 256.03 | 10.94M |
| Oct 1, 2026 | 263.68 | 263.98 | 258.33 | 258.66 | 8.29M |
| Sep 30, 2026 | 267.91 | 268.48 | 264.51 | 264.74 | 6.34M |
| Sep 29, 2026 | 269.11 | 271.89 | 265.59 | 267.57 | 5.62M |
| Sep 28, 2026 | 270.17 | 273.78 | 269.27 | 271.95 | 7.19M |
| Sep 25, 2026 | 271.70 | 272.25 | 269.26 | 271.22 | 4.09M |
| Sep 24, 2026 | 269.52 | 275.23 | 269.01 | 270.68 | 6.32M |
| Sep 23, 2026 | 269.47 | 272.14 | 266.50 | 269.17 | 6.63M |
| Sep 22, 2026 | 267.51 | 270.10 | 265.04 | 269.19 | 5.68M |
| Sep 21, 2026 | 271.74 | 273.73 | 268.50 | 269.47 | 4.49M |
| Sep 18, 2026 | 269.45 | 272.11 | 267.20 | 269.99 | 16.43M |
About Johnson & Johnson
Johnson & Johnson (JNJ) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW BRUNSWICK, NJ. State of incorporation: NJ. Fiscal year ends January 3. SEC CIK 200406.
JNJ board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mary C Beckerle | Director | Apr 27, 2026 |
| Jennifer A Doudna | Director | Apr 27, 2026 |
| Joaquin Duato | CEO and Chairman of the Board | Aug 14, 2026 |
| Marillyn A Hewson | Director | Sep 10, 2026 |
| Paula A Johnson | Director | Apr 27, 2026 |
| Hubert Joly | Director | Apr 27, 2026 |
| John G Morikis | Director | Apr 27, 2026 |
| Mark B. Mcclellan | Director | Apr 27, 2026 |
| Daniel E Pinto | Director | Sep 10, 2026 |
| Mark A Weinberger | Director | Apr 27, 2026 |
| Nadja West | Director | Apr 27, 2026 |
| Eugene A. Woods | Director | Sep 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Vanessa Broadhurst | EVP, Global Corp Affairs | Jul 21, 2026 |
| Thomas Cavanaugh | EVP WW Chair, Innovative Med. | Sep 1, 2026 |
| Robert J Decker | VP Corporate Controller | Mar 3, 2026 |
| Joaquin Duato | CEO and Chairman of the Board | Aug 14, 2026 |
| Elizabeth Forminard | EVP, Chief Legal Officer | Aug 7, 2026 |
| Kristen Mulholland | EVP, Chief HR Officer | Feb 18, 2026 |
| John C Reed | EVP, Innovative Medicine, R&D | May 4, 2026 |
| Timothy Schmid | EVP, WW Chair, MedTech | Sep 4, 2026 |
| James D. Swanson | EVP, CIO | Feb 18, 2026 |
| Jennifer L Taubert | EVP, WWC. Innovative Medicine | Aug 18, 2026 |
| Kathryn E Wengel | EVP, Chief TO and Risk Officer | Jun 12, 2026 |
| Joseph J Wolk | Exec VP, CFO | Feb 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Timothy Schmid | Sale | 22,527 | $274.74 |
| Sep 2, 2026 | Timothy Schmid | Sale | 11,070 | $274.74 |
| Aug 17, 2026 | Jennifer L Taubert | Sale | 15,000 | $263.36 |
| Aug 13, 2026 | Joaquin Duato | Sale | 20,976 | $262.00 |
| Aug 13, 2026 | Joaquin Duato | Sale | 102,315 | $261.00 |
| Aug 6, 2026 | Elizabeth Forminard | Sale | 6,574 | $255.93 |
| Aug 6, 2026 | Elizabeth Forminard | Sale | 9,344 | $257.76 |
| Aug 5, 2026 | Joaquin Duato | Sale | 41,957 | $258.06 |
| Aug 5, 2026 | Joaquin Duato | Sale | 6,523 | $258.74 |
| Jul 20, 2026 | Vanessa Broadhurst | Sale | 23,054 | $251.27 |
| Jun 11, 2026 | Kathryn E Wengel | Sale | 10,000 | $241.15 |
| Feb 27, 2026 | Robert J Decker | Sale | 4,075 | $247.87 |
| Feb 20, 2026 | Timothy Schmid | Sale | 1,322 | $245.66 |
| Feb 18, 2026 | Timothy Schmid | Sale | 8,998 | $244.53 |
| Feb 18, 2026 | Timothy Schmid | Sale | 13,625 | $244.20 |
JNJ financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 28, 2025 | $94.19B | $26.80B | 11.03 | $24.53B |
| Dec 29, 2024 | $88.82B | $14.07B | 5.79 | $24.27B |
| Dec 31, 2023 | $85.16B | $35.15B | 13.72 | $22.79B |
| Jan 1, 2023 | $79.99B | $17.94B | 6.73 | $21.19B |
| Jan 2, 2022 | $78.74B | $20.88B | 7.81 | $23.41B |
Latest balance sheet: total assets $201.06B, total liabilities $116.09B, cash $20.42B (as of Jun 28, 2026).
JNJ earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Oct 13, 2026 | 8-K Item 2.02 (results) | $248.61 |
| Jul 15, 2026 | 8-K Item 2.02 (results) | $247.02 |
| Apr 14, 2026 | 8-K Item 2.02 (results) | $240.10 |
| Jan 21, 2026 | 8-K Item 2.02 (results) | $218.01 |
| Oct 14, 2025 | 8-K Item 2.02 (results) | $190.85 |
| Jul 16, 2025 | 8-K Item 2.02 (results) | $164.78 |
| Apr 15, 2025 | 8-K Item 2.02 (results) | $153.62 |
| Jan 22, 2025 | 8-K Item 2.02 (results) | $145.27 |
| Oct 15, 2024 | 8-K Item 2.02 (results) | — |
| Jul 17, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
| Apr 16, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on JNJ
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.